Cholangiocarcinoma Clinical Trials

29 studies are recruiting for cholangiocarcinoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer

   Background: - Recent advances in cancer research have led to new therapies to treat the disease. It is important to continue these advances and discover new ones. To do that, researchers need tissue samples from solid tumors. This study will collect such samples from people already scheduled to hav…

   Stage

   Not phased

   Ages

   2 and older

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT01915225 on ClinicalTrials.gov

2. A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

   This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713.…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Hoag Memorial Hospital Presbyterian, Newport Beach, California

   Locations

   30 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07213791 on ClinicalTrials.gov

3. PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

   Background: One way to treat liver cancer is to deliver chemotherapy drugs only to the liver (and not to the whole body). Researchers want to see if adding the drug PDS01ADC can improve the treatment. The drug triggers the immune system to fight cancer.<TAB> Objective: To see if treatment with HAIP…

   Stage

   Phase 2

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05286814 on ClinicalTrials.gov

4. Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers

   Background: Cholangiocarcinoma (CCA) is an aggressive cancer of the bile ducts. People with CCA have few treatment options and poor survival. Researchers want to see if a new drug can stop or slow CCA growth. Objective: To find the safest and most effective dose of tivozanib to treat CCA and learn …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT04645160 on ClinicalTrials.gov

5. Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers

   This is a prospective pilot protocol investigating whether ctDNA detection be improved by sampling the cancer draining vein versus the standard practice of sampling from a peripheral vein in patients who are undergoing biopsies for hepatobiliary and pancreatic cancers.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California

   Run by

   University of California, Irvine

   See if you can join NCT05497531 on ClinicalTrials.gov

6. A Study of PHST001 in Advanced Solid Tumors

   This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with chemotherapy (Phase 1b) in adult participants with advanced rela…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Precision NextGen Oncology & Research Center, Beverly Hills, California

   Locations

   20 in total

   Run by

   Pheast Therapeutics

   See if you can join NCT06840886 on ClinicalTrials.gov

7. HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer

   This is a pilot and feasibility study assessing the role of quantitative multiparametric MRI and blood-based biomarkers for the measurement of liver function in patients receiving radiation therapy for liver cancer, including hepatocellular carcinoma (HCC), cholangiocarcinoma, or liver metastases r…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Montefiore Medical Center, The Bronx, New York

   Run by

   Montefiore Medical Center

   See if you can join NCT06899152 on ClinicalTrials.gov

8. Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

   A open-label drug-drug interaction (DDI) study to evaluate the effects of olutasidenib on the pharmacokinetics (PK) of a CYP450 and OATP1B1 probe substrate cocktail in participants with IDH1 mutation-positive malignancies.

   Stage

   Phase 4

   Ages

   18 and older

   Site

   UCI Irvine Health, Orange, California

   Locations

   2 in total

   Run by

   Rigel Pharmaceuticals

   See if you can join NCT07486713 on ClinicalTrials.gov

9. TCR1188-ABC Cells in KRAS-mutated Cancers

   This is a Phase I, open-label dose finding study to assess the safety, manufacturing feasibility, and preliminary efficacy of TCR1188-ABC cells in patients with KRAS-mutated cancers. Initially, patients with KRAS G12V mutation positive metastatic pancreatic adenocarcinoma, cholangiocarcinoma, color…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Run by

   University of Pennsylvania

   See if you can join NCT07594067 on ClinicalTrials.gov

10. Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)

    The overall goal of the WU-PE-CGS is to build a rigorous, scientific evidence base for approaches that direct engagement of cancer patients and post-treatment cancer survivors as participants in cancer research, and to investigate the impact of directly engaging participants in decisions regarding …

    Stage

    Not phased

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT06340646 on ClinicalTrials.gov

11. Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma

    This is an open-label, multicenter Phase 1b/2a study to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of GNS561 in combination with trametinib in Advanced KRAS Mutated Cholangiocarcinoma after failure of standard-of-care first line therapy

    Stage

    Phase 1

    Ages

    18 and older

    Site

    USC Norris Comprehensive Cancer Center, Los Angeles, California

    Locations

    11 in total

    Run by

    Genfit

    See if you can join NCT05874414 on ClinicalTrials.gov

12. An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer

    It is sometimes difficult to precisely understand whether a primary liver cancer is a hepatocellular carcinoma or a cholangiocarcinoma. The researchers will develop and validate a liquid biopsy, based on exosomal content analysis and powered by machine learning, to help clinicians differentiate the…

    Stage

    Not phased

    Ages

    18 and older

    Site

    City of Hope Medical Center, Duarte, California

    Locations

    5 in total

    Run by

    City of Hope Medical Center

    See if you can join NCT06342414 on ClinicalTrials.gov

13. A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer

    Gastrointestinal (GI) cancers remain a major global health burden, largely due to the lack of effective and accessible early screening strategies. Current diagnostic approaches-including endoscopy, computed tomography (CT), and magnetic resonance imaging (MRI)-are either invasive, resource-intensiv…

    Stage

    Not phased

    Ages

    18 and older

    Site

    City of Hope Nat Medical Ctr, Duarte, California

    Run by

    City of Hope Medical Center

    See if you can join NCT07224750 on ClinicalTrials.gov

14. Targeted Navigation in Hepatocellular Carcinoma (HCC)

    The investigators are trying to learn more about the personal perceptions and experiences regarding the needs of patients with liver cancer to help improve the care of all patients. The investigators would like to know whether there are needs that patients have or are aware of, especially those nee…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Miami, Miami, Florida

    Run by

    University of Miami

    See if you can join NCT06260943 on ClinicalTrials.gov

15. TCF-001 TRACK (Target Rare Cancer Knowledge) Study

    This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results.

    Stage

    Not phased

    Ages

    18 and older

    Site

    TargetCancer Foundation, Cambridge, Massachusetts

    Run by

    TargetCancer Foundation

    See if you can join NCT04504604 on ClinicalTrials.gov

16. 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

    Background: Fibroblast-activation protein (FAP) is an enzyme that appears in high numbers in cancer-associated fibroblasts of certain cancer types. [18F]FAPI-74 is a new PET (positron emission tomography) tracer, a substance that is injected into a person s body before an imaging scan. Researchers …

    Stage

    Phase 2

    Ages

    18 to 120

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT06503146 on ClinicalTrials.gov

17. BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

    BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when compared to normal cells. BOLD-100 will be combined with cytotoxic FOLFOX c…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Cross Cancer Institue, Edmonton, Alberta

    Locations

    24 in total

    Run by

    Bold Therapeutics, Inc.

    See if you can join NCT04421820 on ClinicalTrials.gov

18. Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

    This study is researching whether the combination of Afatinib and Pemigatinib is safe and effective in FGFR altered unresectable or metastatic advanced solid tumors. The study is also trying to discover the highest doses of the study drugs that can be administered without causing any intolerable si…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Run by

    Massachusetts General Hospital

    See if you can join NCT06302621 on ClinicalTrials.gov

19. A Study of MGC028 in Participants With Advanced Solid Tumors

    The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defined). The study will enroll adult participants with relapsed or refractory, unresectable, locally ad…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UCSF - Helen Diller Family Cancer Center, San Francisco, California

    Locations

    7 in total

    Run by

    MacroGenics

    See if you can join NCT06723236 on ClinicalTrials.gov

20. Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

    This trial is designed to study a combination of interventions (chemotherapy, immunotherapy, and radiation) as a potential new treatment for bile duct cancer that cannot be removed with surgery. The specific names of the interventions that will be used are: * Y-90 (a type of radiation microsphere b…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Beth Israel Deaconess Medical Center, Boston, Massachusetts

    Run by

    Beth Israel Deaconess Medical Center

    See if you can join NCT05655949 on ClinicalTrials.gov

21. Molecular Epidemiology of Biliary Tree Cancers

    This study is to learn if certain risk factors (environmental, viral, behavioral, medical, and dietary), tumor markers, and genetic changes can predict the development and outcome of biliary tree cancers. Establishing biomarkers models from patients may help doctors to further understand how biliar…

    Stage

    Not phased

    Ages

    Any age

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT05179486 on ClinicalTrials.gov

22. A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma

    To find out if adding pembrolizumab to standard of care chemotherapy drugs (cisplatin and gemcitabine) will improve long-term response of intrahepatic cholangiocarcinoma after surgery, compared to treatment with surgery and standard chemotherapy alone.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT05967182 on ClinicalTrials.gov

23. Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

    This research will have a significant impact on the overall management of those cancer patients and their family members who are at risk for hereditary cancer due to germline inactivation of BAP1. Our study will ultimately facilitate the development of novel screening, prevention and treatment stra…

    Stage

    Not phased

    Ages

    Any age

    Site

    The Ohio State University Wexner Medical Center, Columbus, Ohio

    Run by

    Mohamed Abdel-Rahman

    See if you can join NCT04792463 on ClinicalTrials.gov

24. Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer

    Participants are eligible for this study who were treated for advanced biliary tract cancer (BTC) but the treatment either did not make the cancer better or is no longer working. The treatment for patients whose advanced BTC either did not make the cancer better or is no longer working is a combina…

    Stage

    Phase 2

    Ages

    19 and older

    Site

    University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio

    Locations

    2 in total

    Run by

    Case Comprehensive Cancer Center

    See if you can join NCT07146646 on ClinicalTrials.gov

25. Biobank for Cholestatic Liver Diseases.

    This study is a biobank of specimens and clinical data for use in current and future research to better understand the cholestatic liver diseases primary biliary cirrhosis/cholangitis (PBC) and primary sclerosing cholangitis (PSC).

    Stage

    Not phased

    Ages

    18 to 85

    Site

    Mayo Clinic, Rochester, Minnesota

    Run by

    Mayo Clinic

    See if you can join NCT03445585 on ClinicalTrials.gov